Frequency of JAK2 Mutations in Patients with Suspected Myeloproliferative Neoplasms

被引：0
|
作者：
Judd, A. [1 ]
Chabot-Richards, D. [1 ]
机构：
[1] Univ New Mexico, Albuquerque, NM 87131 USA
来源：
JOURNAL OF MOLECULAR DIAGNOSTICS | 2019年 / 21卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
H005
引用
收藏
页码：1138 / 1138
页数：1
相关论文
共 50 条
  • [41] Altered erythropoiesis via JAK2 and ASXL1 mutations in myeloproliferative neoplasms
    Collinsa, Taylor B.
    Laranjeiraa, Angelo B. A.
    Konga, Tim
    Fulbrighta, Mary C.
    Fishera, Daniel A. C.
    Sturgeona, Christopher M.
    Batistaa, Luis F. Z.
    Oh, Stephen T.
    EXPERIMENTAL HEMATOLOGY, 2024, 132
  • [42] JAK2 inhibition mediates clonal selection of RAS pathway mutations in myeloproliferative neoplasms
    Maslah, N.
    Roux, B.
    Kaci, N.
    Verger, E.
    De Oliveira, R. Daltro
    Pasquer, H.
    Zhao, L. P.
    Gauthier, N.
    Soret-Dulphy, J.
    Ganesan, S.
    Gou, P.
    Ling, F.
    Parquet, N.
    Vainchenker, W.
    Raffoux, E.
    Padua, R. A.
    Giraudier, S.
    Puissant, A.
    Lobry, C.
    Kiladjian, J. J.
    Cassinat, B.
    Benajiba, L.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2023, 37 : 11 - 11
  • [43] Prospect of JAK2 inhibitor therapy in myeloproliferative neoplasms
    Atallah, Ehab
    Verstovsek, Srdan
    EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (05) : 663 - 670
  • [44] Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms
    Neha Bhagwat
    Ross L. Levine
    Priya Koppikar
    International Journal of Hematology, 2013, 97 : 695 - 702
  • [45] Mechanisms of Resistance to JAK2 Inhibitors in Myeloproliferative Neoplasms
    Meyer, Sara C.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2017, 31 (04) : 627 - +
  • [46] Molecular insights into regulation of JAK2 in myeloproliferative neoplasms
    Silvennoinen, Olli
    Hubbard, Stevan R.
    BLOOD, 2015, 125 (22) : 3388 - 3392
  • [47] JAK2 inhibitors for myeloproliferative neoplasms: what is next?
    Bose, Prithviraj
    Verstovsek, Srdan
    BLOOD, 2017, 130 (02) : 115 - 125
  • [48] Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms
    Bhagwat, Neha
    Levine, Ross L.
    Koppikar, Priya
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2013, 97 (06) : 695 - 702
  • [49] FREQUENCY OF JAK2 EXON 12 MUTATIONS IN JAK2 (V617F) NEGATIVE PATIENTS WITH CHRONIC MYELOPROLIFERATIVE DISORDERS (CMD)
    Bernardi, M.
    Ruggeri, M.
    Albiero, E.
    Madeo, D.
    Rodeghiero, F.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 294 - 294
  • [50] Absence of the JAK2 exon 12 mutations in patients with splanchnic venous thrombosis and without overt myeloproliferative neoplasms
    Fiorini, Alessia
    Chiusolo, Patrizia
    Rossi, Elena
    Za, Tommaso
    de Ritis, Daniela G.
    Ciminello, Angela
    Leone, Giuseppe
    de Stefano, Valerio
    AMERICAN JOURNAL OF HEMATOLOGY, 2009, 84 (02) : 126 - 127
12345